Compare DK & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | AMLX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2017 | 2021 |
| Metric | DK | AMLX |
|---|---|---|
| Price | $67.47 | $29.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $39.94 | $21.56 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.67 | 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $25.85 | $10.83 |
| 52 Week High | $82.27 | $41.14 |
| Indicator | DK | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 43.65 |
| Support Level | $63.13 | $12.54 |
| Resistance Level | $68.85 | $34.35 |
| Average True Range (ATR) | 4.06 | 1.56 |
| MACD | -1.57 | -0.83 |
| Stochastic Oscillator | 9.14 | 18.79 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.